Prometheus Biosciences Insiders

Prometheus Biosciences employs about 97 people. The company is managed by 10 executives with a total tenure of roughly 227 years, averaging almost 22.0 years of service per executive, having 9.7 employees per reported executive. Break down of Prometheus Biosciences' management performance can provide insight into the company performance.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in small area income & poverty estimates.

Prometheus Biosciences Management Team Effectiveness

The company has return on total asset (ROA) of (0.2006) % which means that it has lost $0.2006 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.333) %, meaning that it created substantial loss on money invested by shareholders. Prometheus Biosciences' management efficiency ratios could be used to measure how well Prometheus Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.
Prometheus Biosciences owns a total of 47.81 Million outstanding shares. The majority of Prometheus Biosciences outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Prometheus Biosciences to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Prometheus Biosciences. Please pay attention to any change in the institutional holdings of Prometheus Biosciences as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Prometheus Biosciences in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Prometheus Biosciences, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Prometheus Biosciences Workforce Comparison

Prometheus Biosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 204,084. Prometheus Biosciences adds roughly 97.0 in number of employees claiming only tiny portion of equities under Health Care industry.

Prometheus Biosciences Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Prometheus Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Prometheus Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Prometheus Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Prometheus Biosciences Notable Stakeholders

A Prometheus Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Prometheus Biosciences often face trade-offs trying to please all of them. Prometheus Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Prometheus Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
String symbol = request.getParameter("s");

Prometheus Biosciences Workforce Analysis

Traditionally, organizations such as Prometheus Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Prometheus Biosciences within its industry.

Prometheus Biosciences Manpower Efficiency

Return on Prometheus Biosciences Manpower

Revenue Per Employee70.2K
Revenue Per Executive680.9K
Net Loss Per Employee1.5M
Net Loss Per Executive14.2M
Working Capital Per Employee7.1M
Working Capital Per Executive68.5M
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in small area income & poverty estimates.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Other Consideration for investing in Prometheus Stock

If you are still planning to invest in Prometheus Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prometheus Biosciences' history and understand the potential risks before investing.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals